CAS Medical Systems Inc. posted a tiny second-quarter profit as the Branford medical-device maker’s decision to exit unlucrative markets is paying off on its balance sheet.
CAS earned a net $8,000, or zero cents a share, in the three months ended June 30. That compares to a net loss of $800,000, or 7 cents a share, the same period last year.
Revenues were $8.2 million, 4 percent less than the $7.8 million in revenues in the second quarter of 2009, the company said. Shelving products that didn’t sell well accounted for the revenue decline, said CEO Andrew Kersey.
Still, its overall sales, Kersey said, were paced by its Fore-Sight line of noninvasive bedside devices used to monitor blood pressure in newborns and for detecting oxygen levels in adult surgery patients.
The company shipped 33 monitors in the quarter, pushing Fore-Sight sales $400,000 above the $1 million in sales for the April-June period last year.
At 11 a.m., CAS was down 15 cents, or 7 percent, at $2.
